Narrative review highlights visual outcomes and quality of life impacts from discontinuing anti-VEGF therapy in AMD.
Intravitreal anti‐vascular endothelial growth factor (anti‐VEGF) therapy has revolutionised the treatment of neovascular age‐related macular degeneration (nAMD), significantly improving visual outcomes and enhancing the quality of life for affected patients. However, the decision to discontinue anti‐VEGF therapy in nAMD management remains complex and lacks consensus, with various criteria being applied. This narrative review examines the available evidence on the cessation of anti‐VEGF treatment in nAMD in detail.
No takes yet. Share an insight, caveat, or question.
Usmani et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: